Which one can be injected once a quarter?

Ajovy: its label offers 675 mg every 3 months, given as three consecutive 225 mg injections, as an alternative to 225 mg monthly. Emgality's migraine regimen is monthly.

Which one covers cluster headache?

Emgality. Its label includes treatment of episodic cluster headache at 300 mg - three consecutive 100 mg injections - at the onset of the cluster period. The Ajovy label covers migraine prevention only.

Do they work the same way?

Both bind the CGRP molecule itself, unlike Aimovig, which binds the CGRP receptor. The two mechanisms sections read almost identically; the practical differences are in dosing and in who each label covers.

MigraineTwo labels compared

Emgality vs Ajovy

Emgality and Ajovy are the closest pair among the migraine antibodies: both bind the CGRP molecule itself and both are injected for prevention. The differences live at the edges of the documents: Emgality alone covers episodic cluster headache, Ajovy alone offers a quarterly schedule and covers children. This page compares the two labels.

Emgality

Ingredient: Galcanezumab
Approved for: Preventive treatment of migraine, and episodic cluster headachecovers migraine
Supply: Prescription
Boxed warning: None
Pharmacy cost: $734.41 per milliliter, brandwhat pharmacies pay to buy it, not the price at the counter

Eli Lilly and Company. Label version 17, effective 5 June 2026.

Ajovy

Ingredient: Fremanezumab
Approved for: Preventive treatment of migrainecovers migraine
Supply: Prescription
Boxed warning: None
Pharmacy cost: $508.21 per milliliter, brandwhat pharmacies pay to buy it, not the price at the counter

Teva Pharmaceuticals USA, Inc.. Label version 24, effective 5 June 2026.

01From the FDA label

Side by side, straight from the labels

Generated from the two source labels, not typed out by hand, so it cannot drift from what the regulator approved. Rows where both labels say exactly the same thing are marked.

Label section	EmgalityGalcanezumab	AjovyFremanezumab
Active ingredient	EmgalityGalcanezumabCGRP ligand antibody	AjovyFremanezumabCGRP ligand antibody
Approved for	EmgalityPreventive treatment of migraine, and episodic cluster headache	AjovyPreventive treatment of migraine
Supplysame in both	EmgalityPrescription	AjovyPrescription
What pharmacies payAcquisition cost, not retail	Emgality$734.41 per milliliter, brand	Ajovy$508.21 per milliliter, brand
Boxed warningsame in both	EmgalityNone	AjovyNone
What the FDA approved it for	Emgality EMGALITY ® is a calcitonin-gene related peptide antagonist indicated in adults for the: preventive treatment of migraine. treatment of episodic cluster headache.	Ajovy AJOVY is a calcitonin gene-related peptide antagonist indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more.
Forms and strengths	Emgality EMGALITY is a sterile clear to opalescent, colorless to slightly yellow to slightly brown solution available as follows: Injection: 120 mg/mL in a single-dose prefilled pen Injection: 120 mg/mL in a single-dose prefilled syringe Injection: 100 mg/mL in a single-dose prefilled syringe Injection: 120 mg/mL solution in a single-dose prefilled pen Injection: 120 mg/mL solution in a single-dose prefilled syringe Injection: 100 mg/mL solution in a single-dose prefilled syringe	Ajovy AJOVY is a sterile, clear to opalescent, colorless to slightly yellow solution, available as follows: Injection: 225 mg/1.5 mL single-dose prefilled autoinjector Injection: 225 mg/1.5 mL single-dose prefilled syringe Injection: 225 mg/1.5 mL solution in a single-dose prefilled autoinjector. Injection: 225 mg/1.5 mL solution in a single-dose prefilled syringe.
How the label says it is taken	Emgality For subcutaneous use only. Migraine recommended dosage: 240 mg loading dose (administered as two consecutive injections of 120 mg each), followed by monthly doses of 120 mg. Episodic cluster headache recommended dosage: 300 mg (administered as three consecutive injections of 100 mg each) at the onset of the cluster period, and then monthly until the end of the cluster period. Administer in the abdomen, thigh, back of the upper arm, or buttocks subcutaneously.	Ajovy For subcutaneous use only. Recommended dosage: Adults: Two subcutaneous dosing options of AJOVY are available to administer the recommended dosage; 225 mg monthly or 675 mg every 3 months (quarterly). The 675 mg quarterly dosage is administered as three consecutive injections of 225 mg each. Pediatric patients 6 to 17 years of age and who weigh 45 kg or more: 225 mg monthly Administer in the abdomen, thigh, or upper arm subcutaneously. See Dosage and Administration for important administration instructions.
Most common adverse reactions	Emgality most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in EMGALITY clinical studies were injection site reactions. most common adverse reaction was injection site reactions. In Studies 1, 2, and 3, 1.8% of patients discontinued double-blind treatment because of adverse events.	Ajovy most common adverse reactions (≥5% and greater than placebo) were injection site reactions. most common adverse reactions in the clinical trials for the preventive treatment of migraine (incidence at least 5% and greater than placebo) were injection site reactions. most common adverse reactions of AJOVY observed in Study 3 were injection site reactions.
Warnings and precautions	Emgality Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue administration of EMGALITY and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration, and may be prolonged. Constipation with Serious Complications: Serious complications of constipation may occur. Hypertension: New-onset or worsening of pre-existing hypertension may occur. Raynaud's Phenomenon: New-onset or worsening of pre-existing Raynaud's phenomenon may occur.	Ajovy Hypersensitivity Reactions: Most reactions were reported from within hours to one month after administration. If hypersensitivity occurs, consider discontinuing AJOVY and institute appropriate therapy. Constipation with Serious Complications: Serious complications of constipation may occur. Hypertension: New-onset or worsening of pre-existing hypertension may occur. Raynaud's Phenomenon: New-onset or worsening of pre-existing Raynaud's phenomenon may occur.
Contraindications	Emgality EMGALITY is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.	Ajovy AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema.
Label versionsame in both	Emgality5 June 2026	Ajovy5 June 2026

02Written by us

The shared core: a ligand antibody for prevention

Both labels describe humanized monoclonal antibodies that bind calcitonin gene-related peptide and block its binding to the receptor, and both cover the preventive treatment of migraine. Neither treats an attack in progress, and neither label carries a boxed warning.

03Written by us

Each label reaches somewhere the other does not

Emgality holds a second indication: treatment of episodic cluster headache, with its own regimen of 300 mg at the onset of a cluster period. Nothing similar appears in the Ajovy label.

Ajovy reaches in two other directions: a quarterly option - 675 mg every 3 months as three consecutive injections - alongside the monthly 225 mg, and a pediatric indication for episodic migraine in patients 6 to 17 years old weighing 45 kg or more. Emgality's migraine dosing is monthly, 120 mg after a 240 mg loading dose, in adults.

04Written by us

What this page does not tell you

It does not rank the two antibodies. They were approved on separate trial programs, and their labels do not compare them; the choice, including whether an antibody is the right approach at all, belongs to a prescriber.

05Written by us

Common questions

Which one can be injected once a quarter?: Ajovy: its label offers 675 mg every 3 months, given as three consecutive 225 mg injections, as an alternative to 225 mg monthly. Emgality's migraine regimen is monthly.
Which one covers cluster headache?: Emgality. Its label includes treatment of episodic cluster headache at 300 mg - three consecutive 100 mg injections - at the onset of the cluster period. The Ajovy label covers migraine prevention only.
Do they work the same way?: Both bind the CGRP molecule itself, unlike Aimovig, which binds the CGRP receptor. The two mechanisms sections read almost identically; the practical differences are in dosing and in who each label covers.

Sources

Every fact above comes from one of these documents. The date is the effective date of the label version this page was built from.

FDA prescribing information for Emgality
Eli Lilly and Company. Label version 17, effective 5 June 2026.
Full label on DailyMed Approval record BLA761063
FDA prescribing information for Ajovy
Teva Pharmaceuticals USA, Inc.. Label version 24, effective 5 June 2026.
Full label on DailyMed Approval record BLA761089

Each stripe is one section of the label, each division in a stripe one entry in that section.

Other comparisons in this category

Page last updated 29 August 2026

Compiled by the HealthyStudy editorial team from FDA source documents. No medical reviewer is credited on this page, because none reviewed it.